GLPG - Galapagos NV

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
104.75
-1.51 (-1.42%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close106.26
Open105.04
Bid102.90 x 1300
Ask105.22 x 1000
Day's Range104.29 - 105.21
52 Week Range85.00 - 122.28
Volume57,013
Avg. Volume110,862
Market Cap5.668B
Beta (3Y Monthly)1.70
PE Ratio (TTM)N/A
EPS (TTM)-1.69
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est126.72
Trade prices are not sourced from all markets
  • GlobeNewswire12 days ago

    Sands Capital reports 5.7% holding in Galapagos

    Mechelen, Belgium; 8 January 2019; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Sands Capital.

  • GlobeNewswire13 days ago

    Galapagos starts first Phase 1 trial with Toledo compound

    7 January 2019, 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) initiated a Phase 1 trial with GLPG3312, a first generation compound against a novel and undisclosed inflammation target class discovered by Galapagos. "We are excited by the rapid progression of our Toledo program into the clinic," said Dr. Piet Wigerinck, Chief Scientific Officer at Galapagos.

  • GlobeNewswire14 days ago

    Galapagos initiates NOVESA Phase 2a trial in patients with systemic sclerosis

    6 January 2019, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) expands its clinical study program with GLPG1690 in systemic sclerosis, following the recent start of the ISABELA Phase 3 program with '1690 in IPF. NOVESA is a double-blind, placebo-controlled Phase 2a trial evaluating the efficacy, safety and PK/PD of '1690 in patients with systemic sclerosis (SSc, or scleroderma). NOVESA is planned to recruit 30 patients with diffuse cutaneous SSc, an autoimmune disease involving multiorgan fibrosis, which has one of the highest mortality rates among rheumatic diseases[1].

  • GlobeNewswire16 days ago

    Fibrocor and Galapagos sign partnership in fibrosis

    4 January 2019, 22.01 CET - Fibrocor Therapeutics L.P. (Fibrocor), a privately held Canadian company, and Galapagos NV (Euronext & NASDAQ: GLPG) announced a global partnership focused on a novel target for idiopathic pulmonary fibrosis (IPF) and other indications. In exchange for global commercialization rights to Galapagos, Fibrocor will receive an upfront payment, and potentially is eligible for further milestone and royalty payments. Galapagos will be responsible for all further development of the program.

  • AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions
    Zacks24 days ago

    AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions

    AMAG's (AMAG) share improve 9.7% year to date courtesy of label expansion efforts as well as acquisitions and deals.

  • How Should Investors React To Galapagos NV’s (AMS:GLPG) CEO Pay?
    Simply Wall St.25 days ago

    How Should Investors React To Galapagos NV’s (AMS:GLPG) CEO Pay?

    In 1999 Onno van de Stolpe was appointed CEO of Galapagos NV (AMS:GLPG). First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at Read More...

  • GlobeNewswirelast month

    Galapagos to Present at 37th Annual J.P. Morgan Healthcare Conference

    Mechelen, Belgium; 21 December 2018, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 37th Annual J.P. Morgan Healthcare Conference on January 8.

  • GlobeNewswirelast month

    Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)

    17 December 2018, 22.15 CET - Galapagos NV (Euronext & NASDAQ: GLPG) today announces that it has dosed its first patient in the worldwide ISABELA Phase 3 program with autotaxin inhibitor GLPG1690 in IPF. "Today's news again demonstrates our commitment to the rapid advancement of our IPF franchise, including the ISABELA and the PINTA trials. GLPG1690 is a small molecule, selective autotaxin inhibitor which is fully proprietary to Galapagos.

  • GlobeNewswirelast month

    Recent Analysis Shows Best Buy Co., News Corporation, Semtech, Achaogen, Infosys, and Galapagos NV Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Dec. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Galapagos' Osteoarthritis Candidate Gets Fast Track Status
    Zacks2 months ago

    Galapagos' Osteoarthritis Candidate Gets Fast Track Status

    Galapagos' (GLPG) GLPG1972/S201086 gets Fast Track designation by the FDA for the treatment of osteoarthritis.

  • GlobeNewswire2 months ago

    Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis

    27 November 2018, 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that the FDA has granted GLPG1972/S201086 Fast Track designation for the treatment of patients with osteoarthritis (OA). The US Food and Drug Administration's (FDA's) Fast Track program is designed to facilitate the development and expedite the review of drugs that treat serious or life-threatening diseases or conditions and that demonstrate the potential to address unmet medical needs. Drugs that receive this designation are eligible for more frequent interactions with the FDA and are potentially eligible for priority review and rolling review of a New Drug Application (NDA).

  • 5 Biotech Stocks to Scoop Up for Big Dividends
    InvestorPlace2 months ago

    5 Biotech Stocks to Scoop Up for Big Dividends

    When it comes to biotech stocks, the perception is that the sector is a gamble. Many investors believe that most biotech stocks are clinical-stage lotto tickets that will only succeed on a wish and a prayer. It’s here that investors can find stable cash flows, profits, and even dividend stocks.

  • GlobeNewswire2 months ago

    Transparency notification

    Mechelen, Belgium; 26 November 2018; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Van Herk Investments.

  • GlobeNewswire2 months ago

    Galapagos increases share capital through warrant exercises

    Mechelen, Belgium; 23 November 2018, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant.

  • Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids
    Zacks2 months ago

    Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids

    CHMP gives positive opinion to Vertex's (VRTX) label expansion of Orkambi.

  • Why Galapagos (GLPG) Might Surprise This Earnings Season
    Zacks2 months ago

    Why Galapagos (GLPG) Might Surprise This Earnings Season

    Galapagos (GLPG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • GlobeNewswire3 months ago

    Galapagos reports initiation of PINTA Phase 2 trial with GLPG1205 in patients with Idiopathic Pulmonary Fibrosis (IPF)

    PINTA is a randomized, double-blind, placebo-controlled Phase 2 trial investigating a 100 mg once-daily oral dose of GLPG1205 in up to 60 IPF patients. "The first patient dosing in our PINTA Phase 2 trial shows the progress we are making in expanding our IPF franchise," said Dr. Piet Wigerinck, Chief Scientific Officer at Galapagos.

  • GlobeNewswire3 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within ICON, Robert Half International, CenterPoint Energy, Galapagos NV, Canadian Pacific Railway, and Mobile Mini — New Research Emphasizes Economic Growth

    NEW YORK, Oct. 29, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Simply Wall St.3 months ago

    All You Need To Know About Galapagos NV’s (AMS:GLPG) Financial Health

    Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Galapagos NV (AMS:GLPG), with a market capitalization of €4.9b, rarely draw their attention from the investing community. Read More...

  • PR Newswire3 months ago

    AbbVie to Assume Full Development and Commercial Control of Cystic Fibrosis Research Program

    NORTH CHICAGO, Ill., Oct. 24, 2018 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, announced today that it will assume full development and commercial responsibility for its collaboration with Galapagos (GLPG.NX) to discover and develop new therapies to treat cystic fibrosis (CF). AbbVie's research program aims to develop a best-in-class, triple-combination therapy for patients living with cystic fibrosis. Currently in early clinical development, the program consists of mechanistically distinct drug-candidates, termed "potentiators" and "correctors", which collectively increase the activity of the mutated copies of the cystic fibrosis transmembrane conductance regulator (CFTR) protein that causes CF.

  • GlobeNewswire3 months ago

    Hallmark third quarter 2018 and Annual R&D Update at Galapagos

    First nine months financial results: Group revenues increased by €98.7 million to €205.1 million Operating loss decreased by €9.1 million to €53.5 million Net loss.

  • GlobeNewswire3 months ago

    Galapagos and AbbVie restructure CF collaboration

    AbbVie takes over all programs in CF and continues the development of a triple combination therapy for CF. AbbVie will obtain exclusive worldwide rights to the current CF investigational drug candidate portfolio developed by the two companies in the course of the collaboration. AbbVie will be responsible for all future activities and will bear all costs associated with this portfolio in CF going forward.

  • GlobeNewswire3 months ago

    Topline interim results of FALCON trial Part 1 in CF

    The FALCON trial is a phase 1b, multi-center, open-label, non-randomized, multiple cohorts study to assess the safety, tolerability, pharmacokinetics, and efficacy of a novel combination treatment of GLPG2451 and GLPG2222, with and without GLPG2737, in up to 24 adult patients with CF. The FALCON study's primary objectives include safety and PK. Secondary objectives include changes in pharmacodynamic biomarkers for CFTR activity (sweat chloride concentration and ppFEV1).

  • Business Wire3 months ago

    Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet

    Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that detailed results from two clinical trials evaluating filgotinib, an investigational, selective JAK1 inhibitor, for the treatment of psoriatic arthritis and ankylosing spondylitis were both published in The Lancet. “The results of the EQUATOR and TORTUGA studies demonstrate that filgotinib improved the signs and symptoms of patients with psoriatic arthritis whose disease had not responded to prior therapies and independently, for those with ankylosing spondylitis,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences.